AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$254.64-0.05%
Close 2026-07-07 · 1-day change
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is characterized as a durable compounder with a focus on long-term growth. The current thesis state is intact, supported by strong recent financial performance and a positive price reaction following an acquisition announcement.
The market appears to be pricing in a premium compared to peers, indicating high expectations for ABBV's future performance. There is an expectations gap of 0.18, suggesting that investors anticipate continued growth but may be cautious due to the company's current valuation being considered expensive.
Fundamentals are likely to remain strong, given the robust earnings quality and ongoing management priorities focused on increasing earnings per share and advancing the product pipeline. However, there is a low probability of missing earnings expectations, despite a history of consecutive misses.
The long-term thesis hinges on the performance of sector bellwethers like LLY, JNJ, and MRK, which could influence ABBV's trajectory. Additionally, management's ability to execute on their priorities, particularly in advancing the pipeline and increasing earnings guidance, will be crucial.
Overall, ABBV presents a solid long-term thesis, but investors should remain aware of the high valuation and the potential impact of sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Recent advances in AbbVie's pipeline and regulatory approvals support this view. The acquisition of Apogee enhances growth and strengthens its immunology leadership. There are no new threats to the thesis at this time.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Closing the Apogee deal could enhance AbbVie's immunology portfolio. This may lead to stronger revenue growth in the future.
Confirms:The deal will close in Q3 2026. It needs regulatory and shareholder approvals first.
Disproves:The deal does not close. This is due to regulatory issues or shareholder rejection.
Why it matters: An increase in EPS guidance would signal strong operational performance and growth.
Confirms:AbbVie raises adjusted EPS guidance for 2026 above $14.28.
Disproves:AbbVie maintains or lowers adjusted EPS guidance below $14.08.
Why it matters: Approval would give a new treatment option. It would help AbbVie’s immunology portfolio.
Confirms:FDA approves Rinvoq for severe hair loss.
Disproves:FDA denies approval or delays decision on Rinvoq.
Why it matters: Approval would allow more people to use Skyrizi. This could lead to big revenue growth.
Confirms:FDA approves Skyrizi for use in adult patients with Crohn's disease.
Disproves:FDA denies Skyrizi approval or asks for more data on Crohn's disease.
Why it matters: Successful debt issuance helps AbbVie with its capital strategy. It supports future investments.
Confirms one read:Completion of the $750M debt issuance announced in 2026-Q1.
Confirms the other:Failure to complete the planned debt issuance.
Why it matters: Good results may help ABBV-295 become a treatment for weight management.
Confirms:Positive topline results from the Phase 1 study of ABBV-295 are announced.
Disproves:Bad results or safety issues come up in the ongoing study.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.